LGALS3 and Hepatic fibrosis: GR-MD-02 (galactoarabino-rhamnogalacturonate) is a potent inhibitor of Galectin-3 [96] that showed remarkable therapeutic effects in thioacetamide-induced liver fibrosis in rats [97] and was submitted for 3 clinical studies concerning liver fibrosis.